Molecular modeling studies of the binding modes of aldose reductase inhibitors at the active site of human aldose reductase.

Molecular modeling studies using the CHARMM method have been conducted to study the binding modes of aldose reductase inhibitors at the active site of aldose reductase. The energy minimized structures of aldose reductase with six structurally diverse inhibitors (spirofluorene-9,5'-imidazolidine-2',4'-dione (1), 9-fluoreneacetic acid (2), AL1576 (3), 2,7-difluoro-9-fluoreneacetic acid (4), FK366 (5), and Epalrestat (9)) indicate that the side chains of Tyr48, His110, and Trp111 can form numerous hydrogen bonds with either the carboxylate or the hydantoin group of the inhibitors while the side chains of Trp20, Trp111, and Phe122 are positioned to form aromatic-aromatic interactions. Of the three residues (Tyr 48, His 110, and Trp 111) that can form hydrogen bonds with the ionized portion of aldose reductase inhibitors, protonated His110 appears to play an important role in directing charged inhibitors to bind at the active site through charge interaction. Based on the binding mode of the inhibitors and their observed inhibitory activities, pharmacophore requirements for aldose reductase inhibitors are discussed.

[1]  D. Moras,et al.  A 'specificity' pocket inferred from the crystal structures of the complexes of aldose reductase with the pharmaceutically important inhibitors tolrestat and sorbinil. , 1997, Structure.

[2]  G. Rastelli,et al.  Synthesis, activity, and molecular modeling of a new series of tricyclic pyridazinones as selective aldose reductase inhibitors. , 1996, Journal of medicinal chemistry.

[3]  M Hodoscek,et al.  Catalytic mechanism of aldose reductase studied by the combined potentials of quantum mechanics and molecular mechanics. , 1998, Biophysical chemistry.

[4]  G A Petsko,et al.  Aromatic-aromatic interaction: a mechanism of protein structure stabilization. , 1985, Science.

[5]  P. Kador,et al.  Inhibition of aldehyde reductase by aldose reductase inhibitors. , 1990, Biochemical pharmacology.

[6]  J. L. Stein,et al.  Synthesis and aldose reductase inhibitory activity of substituted 2-oxoquinoline-1-acetic acid derivatives. , 1986, Journal of medicinal chemistry.

[7]  T. Nakano,et al.  Kinetic and spectroscopic evidence for active site inhibition of human aldose reductase. , 1996, Biochemistry.

[8]  F A Quiocho,et al.  An unlikely sugar substrate site in the 1.65 A structure of the human aldose reductase holoenzyme implicated in diabetic complications. , 1992, Science.

[9]  J. Bertino,et al.  Ab initio studies of aromatic-aromatic and aromatic-polar interactions in the binding of substrate and inhibitor to dihydrofolate reductase. , 2009, International journal of peptide & protein research.

[10]  P. Kador.  The role of aldose reductase in the development of diabetic complications , 1988, Medicinal research reviews.

[11]  Y. Akagi,et al.  Prevention of pericyte ghost formation in retinal capillaries of galactose-fed dogs by aldose reductase inhibitors. , 1988, Archives of ophthalmology.

[12]  G. Petsko,et al.  An anion binding site in human aldose reductase: mechanistic implications for the binding of citrate, cacodylate, and glucose 6-phosphate. , 1994, Biochemistry.

[13]  Irina Massova,et al.  Comparative molecular field analysis of the antitumor activity of 9H-thioxanthen-9-one derivatives against pancreatic ductal carcinoma 03. , 1994, Journal of medicinal chemistry.

[14]  G. Rastelli,et al.  Structure-based design of an inhibitor modeled at the substrate active site of aldose reductase , 1997 .

[15]  F. G. Prendergast,et al.  Mechanism of aldose reductase inhibition: binding of NADP+/NADPH and alrestatin-like inhibitors. , 1994, Biochemistry.

[16]  F. Quiocho,et al.  1.7 A structure of FR-1, a fibroblast growth factor-induced member of the aldo-keto reductase family, complexed with coenzyme and inhibitor. , 1995, Biochemistry.

[17]  M. Karplus,et al.  CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .

[18]  B. Mylari,et al.  Novel, potent aldose reductase inhibitors: 3,4-dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl] methyl]-1-phthalazineacetic acid (zopolrestat) and congeners. , 1991, Journal of medicinal chemistry.

[19]  C. Lai,et al.  Human aldose reductase: pK of tyrosine 48 reveals the preferred ionization state for catalysis and inhibition. , 1995, Biochemistry.

[20]  J. Kinoshita,et al.  Aldose reductase in the diabetic eye. XLIII Edward Jackson memorial lecture. , 1986, American journal of ophthalmology.

[21]  F A Quiocho,et al.  Refined 1.8 A structure of human aldose reductase complexed with the potent inhibitor zopolrestat. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[22]  J. Sredy,et al.  (Pyrimidinyloxy)acetic acids and pyrimidineacetic acids as a novel class of aldose reductase inhibitors. , 1990, Journal of medicinal chemistry.

[23]  M. Asao,et al.  Biological activities and quantitative structure-activity relationships of spiro[imidazolidine-4,4'(1'H)-quinazoline]-2,2',5(3'H)-triones as aldose reductase inhibitors. , 1992, Journal of medicinal chemistry.

[24]  N. Sharpless,et al.  Aldose reductase inhibitors: a potential new class of agents for the pharmacological control of certain diabetic complications. , 1985, Journal of medicinal chemistry.

[25]  O. El-Kabbani,et al.  Studies on the inhibitor‐binding site of porcine aldehyde reductase: Crystal structure of the holoenzyme‐inhibitor ternary complex , 1997, Proteins.

[26]  P. Kador,et al.  Identification of an aldose reductase inhibitor site by affinity labeling. , 1995, Bioorganic & medicinal chemistry.

[27]  P. Kador,et al.  Human kidney aldose and aldehyde reductases. , 1993, Journal of diabetes and its complications.

[28]  M. Malamas,et al.  Quinazolineacetic acids and related analogues as aldose reductase inhibitors. , 1991, Journal of medicinal chemistry.